Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
Isabelle Fleury, Sylvie Chevret, Michael Pfreundschuh, et al.
Annals of Oncology (2015) Vol. 27, Iss. 3, pp. 390-397
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children
Véronique Minard‐Colin, Anne Aupérin, Marta Pillon, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 23, pp. 2207-2219
Open Access | Times Cited: 255
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Celine Kaegi, Benjamin Wuest, Jens Schreiner, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 202
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Stephen L. Hauser, Ludwig Kappos, Xavier Montalbán, et al.
Neurology (2021) Vol. 97, Iss. 16
Open Access | Times Cited: 123
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Léorah Freeman, Erin E. Longbrake, Patricia K. Coyle, et al.
CNS Drugs (2022) Vol. 36, Iss. 12, pp. 1285-1299
Open Access | Times Cited: 79
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
Matthieu Jestin, Y. Benhamou, An‐Sofie Schelpe, et al.
Blood (2018) Vol. 132, Iss. 20, pp. 2143-2153
Open Access | Times Cited: 131
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
Elisa Lucchini, Francesco Zaja, James B. Bussel
Haematologica (2019) Vol. 104, Iss. 6, pp. 1124-1135
Open Access | Times Cited: 84
Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults
Casey L. McAtee, Joseph Lubega, Kristen Underbrink, et al.
JAMA Network Open (2021) Vol. 4, Iss. 2, pp. e2036321-e2036321
Open Access | Times Cited: 66
Anticancer therapy-induced adverse drug reactions in children and preventive and control measures
Hui Yan, Penggao Wang, Fang Yang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 9
Rituximab: 13 open questions after 20years of clinical use
Francesca Pavanello, Emanuele Zucca, Michele Ghielmini
Cancer Treatment Reviews (2016) Vol. 53, pp. 38-46
Closed Access | Times Cited: 56
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
Sandra Lockmer, Bjørn Østenstad, Hans Hagberg, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 33, pp. 3315-3323
Open Access | Times Cited: 51
Adverse events linked with the use of chimeric and humanized anti‐CD20 antibodies in children with idiopathic nephrotic syndrome
Alice Bonanni, Marta Calatroni, Matteo D’Alessandro, et al.
British Journal of Clinical Pharmacology (2018) Vol. 84, Iss. 6, pp. 1238-1249
Open Access | Times Cited: 50
Rituximab With Involved Field Irradiation for Early‐stage Nodal Follicular Lymphoma
Klaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.
HemaSphere (2018) Vol. 2, Iss. 6
Open Access | Times Cited: 46
Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era
Tao Li, Christina A. Clarke, Aaron S. Rosenberg, et al.
British Journal of Haematology (2017) Vol. 178, Iss. 1, pp. 72-80
Open Access | Times Cited: 44
Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab
Koichi Kamei, Kenji Ishikura, Mayumi Sako, et al.
Pediatric Nephrology (2017) Vol. 32, Iss. 11, pp. 2071-2078
Closed Access | Times Cited: 43
Rituximab in connective tissue disease–associated interstitial lung disease
Ana Catarina Duarte, Filipa Cordeiro, Bruno Miguel Fernandes, et al.
Clinical Rheumatology (2019) Vol. 38, Iss. 7, pp. 2001-2009
Closed Access | Times Cited: 42
Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
Joel Joelsson, Tove Wästerlid, Richard Rosenquist, et al.
Blood Advances (2022) Vol. 6, Iss. 8, pp. 2657-2666
Open Access | Times Cited: 20
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 4
Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
Kazumoto Iijima, Mayumi Sako, Koichi Kamei, et al.
Pediatric Nephrology (2017) Vol. 33, Iss. 9, pp. 1449-1455
Open Access | Times Cited: 36
Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis
Nicole Bou Rjeily, Ellen M. Mowry, Daniel Ontaneda, et al.
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 185-201
Closed Access | Times Cited: 11
Single‐dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open‐label, randomized noninferiority trial
Panjing Wang, Rongfu Zhou, Feng Xue, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 1, pp. 28-37
Closed Access | Times Cited: 10
Mucosal Schwann Cell Hamartoma of the Appendix: Expanding the Differential for Gastrointestinal Bleeding
Abdulmalik Saleem, Taher Jamali, Iana Gueorguieva
ACG Case Reports Journal (2025) Vol. 12, Iss. 5, pp. e01708-e01708
Open Access
Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center
Brett Alldredge, Allison Jordan, Jaime Imitola, et al.
Clinical Neuropharmacology (2018) Vol. 41, Iss. 2, pp. 56-59
Closed Access | Times Cited: 32
Evaluation of pyrrole-2,3-dicarboxylate derivatives: Synthesis, DFT analysis, molecular docking, virtual screening and in vitro anti-hepatic cancer study
Iqbal Azad, Asif Jafri, Tahmeena Khan, et al.
Journal of Molecular Structure (2018) Vol. 1176, pp. 314-334
Closed Access | Times Cited: 29
Rituximab treatment of ANCA-associated vasculitis
L. Raffray, Loı̈c Guillevin
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 8, pp. 899-910
Closed Access | Times Cited: 25
Anti-CD20 antibody treatment of non-Hodgkin lymphomas
M. Engelhard
Clinical Immunology (2016) Vol. 172, pp. 101-104
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top